

BioSpect


the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

BD India announces national launch of Sherlock 3CG+ to improve PICC line placement in cancer patients

31 October 2025 | News

To reduce malposition rates and enable immediate repositioning when necessary



BD (Becton, Dickinson and Company) India has announced the national launch of Sherlock 3CG+ recently through a 4-city roadshow in Delhi, Mumbai, Chennai and Kolkata. In current Indian clinical practice, typically for cancer patients and long term IV access, confirming PICC tip placement involves transferring patients for radiological imaging, which can lead to delays, workflow disruptions, and patient discomfort.

Sherlock 3CG+ addresses these challenges by allowing clinicians to live track and navigate PICC lines and confirm tip placement in real time, directly at the bedside. This advancement is expected to reduce malposition rates and enable immediate repositioning when necessary.

Global clinical evidence has shown malposition rate of PICC tip through blind insertion/ Chest X-ray to be in the range of ~20%. The same evidence has also shown time taken from insertion of PICC line to confirmation of PICC tip through Chest Xray to be approximately 176 mins. Sherlock 3CG+ system enables live tracking and navigation of PICC lines, along with bedside tip confirmation using ECG, eliminating the need for post-placement chest X-rays. The rate of PICC tip malposition in insertions done through Sherlock 3CG+ system was found to be 0% whereas the time taken for insertion to confirmation was reduced to 33 mins¹. The Sherlock 3CG+ is a device that offers Indian clinicians a bedside solution for PICC Tip Confirmation.

Commenting on the launch, Atul Grover, Managing Director, BD India/South Asia said, “Aligned with our purpose of advancing the world of health, BD has been at the forefront of introducing innovative technologies and training HCP’s continuously towards best practices for enhanced patient care. With the launch of our Sherlock 3CG+ we are confident of further supporting Indian clinicians with technologies that align with evolving clinical needs and improve procedural outcomes that enable patient comfort.”